智通财经APP获悉，三生制药(01530)午前涨近3%，截至发稿，涨2.46%，报29.15港元，成交额6.39亿港元。
消息面上，近日，三生制药公布，公司与辉瑞就PD-1/VEGF双特异性抗体(SSGJ-707)订立的许可协议之所有先决条件已达成，许可协议自7月24日起生效。招银国际指出，辉瑞计划快速推进707在全球的III期临床试验，评估其单药及联用化疗、ADCs等联合疗法的潜力。辉瑞拥有丰富的临床资源和先进的ADC药物储备，如PADCEV、sigvotatug vedotin和PDL1V，这些都将有助于加速707的开发进程。
该行认为，707具备多重差异化特征，具有潜在同类最佳的抗血管生成活性及对PD-1的高亲和力，其四价结构和“链式联动”效应可实现更优的VEGF与PD-1协同结合，增强抗肿瘤活性并改善安全性和耐受性。在ASCO上公布的数据显示，在34例10mg/kg Q3W患者中，cORR达64.7%，展示了深度和持久的疾病缓解效果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.